Matthew Donofrio, MD
Internal Medicine · Greensburg, PANPI 1285607705
Payments from drug & device makers
Across 498 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$937
- Pfizer$737
- AstraZeneca$684
- Lilly USA, LLC$665
- Amgen$562
- Abbott$538
- plus $4K from 32 others
What the payments were for
- Food & beverage$8,091100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 72 | $937 |
| Pfizer | 51 | $737 |
| AstraZeneca | 42 | $684 |
| Lilly USA, LLC | 43 | $665 |
| Amgen | 37 | $562 |
| Abbott | 17 | $538 |
| Novo Nordisk | 32 | $476 |
| Boehringer Ingelheim | 26 | $413 |
| Merck | 21 | $348 |
| Novartis | 15 | $248 |
| Bayer | 13 | $241 |
| GSK | 12 | $229 |
| Johnson & Johnson | 15 | $211 |
| Astellas Pharma US Inc | 12 | $210 |
| Sanofi-aventis U.S. LLC | 14 | $196 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $160 |
| E.r. Squibb & Sons, L.L.C. | 10 | $152 |
| Eisai Inc. | 6 | $112 |
| Exact Sciences | 5 | $99 |
| Esperion Therapeutics, Inc. | 5 | $86 |
| Nestle Healthcare Nutrition Inc. | 5 | $83 |
| Boston Scientific | 3 | $73 |
| Phathom Pharmaceuticals, Inc. | 3 | $67 |
| Shield Therapeutics Inc | 3 | $61 |
| Seqirus USA Inc | 3 | $57 |
| Aimmune Therapeutics, Inc. | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $36 |
| Dexcom, Inc. | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Edwards Lifesciences | 1 | $32 |
| Biogen | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$100
How this compares
$8,091 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 457 | $337,268 |
| OzempicSemaglutide | 176 | $199,628 |
| JardianceEmpagliflozin | 198 | $199,008 |
| FarxigaDapagliflozin Propanediol | 199 | $160,390 |
| TrulicityDulaglutide | 121 | $126,172 |
| TradjentaLinagliptin | 116 | $107,677 |
| XareltoRivaroxaban | 120 | $96,394 |
| MounjaroTirzepatide | 56 | $58,305 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $47,934 |
| Repatha SureclickEvolocumab | 76 | $43,648 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 130 | $40,590 |
| MyrbetriqMirabegron | 66 | $40,418 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 145 | $32,339 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $23,494 |
| EntrestoSacubitril/Valsartan | 20 | $23,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat, Stiolto Respimat | $413 | $349,508377 claims |
| PfizerEliquis | $737 | $337,268457 claims |
| Novo NordiskOzempic | $476 | $199,628176 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $665 | $184,476177 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta, Anoro Ellipta | $229 | $162,410390 claims |
| AstraZenecaFarxiga | $684 | $160,390199 claims |
| Johnson & JohnsonXarelto, Invokana | $211 | $106,888133 claims |
| MerckJanumet Xr, Januvia, Janumet | $348 | $43,44057 claims |
| Astellas Pharma US IncMyrbetriq | $210 | $40,41866 claims |
| AbbVieCreon, Synthroid | $937 | $27,466186 claims |
| NovartisEntresto | $248 | $23,06520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Greensburg
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.